| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/14/2006 | US6997863 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 02/14/2006 | CA2450740C Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/14/2006 | CA2378533C Erythropoietin conjugates with polyethylenglycol |
| 02/14/2006 | CA2269072C Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 02/14/2006 | CA2218945C 4-aminoquinazoline derivatives |
| 02/14/2006 | CA2190148C Oral liquid alendronate formulations |
| 02/14/2006 | CA2163197C Tri(platinum) complexes |
| 02/14/2006 | CA2130618C Stereoselective process for preparing .beta.-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonate intermediates |
| 02/10/2006 | CA2504451A1 Dendritic cell vaccines for treating cancer made from embryonic stem cells |
| 02/09/2006 | WO2006015124A2 Fused ring heterocycle kinase modulators |
| 02/09/2006 | WO2006014903A2 Compositions and methods of use for adam12 antagonists in treating disease |
| 02/09/2006 | WO2006014653A1 Induction of apoptosis in toll-like receptor expressing tumor cells |
| 02/09/2006 | WO2006014335A2 Compositions and methods for treatment of non-hodgkin’s lymphoma |
| 02/09/2006 | WO2006013948A1 Triazole derivative |
| 02/09/2006 | WO2006013873A1 Drugs having cyclooxygenase inhibiting activity |
| 02/09/2006 | WO2006013472A2 Novel anti-igf-ir antibodies and uses thereof |
| 02/09/2006 | WO2006013420A2 Mixture of catechins or rather polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy (bph) |
| 02/09/2006 | WO2006013376A2 Drug delivery of a cox inhibitor from embolic agents |
| 02/09/2006 | WO2006013003A1 Use of products derived from selenoprotein t, in its application related to calcium homeostasis |
| 02/09/2006 | WO2006012958A2 Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide |
| 02/09/2006 | WO2005094864A3 Treatment of hedgehog- and wnt-secreting tumors with inhibitors of lipoprotein particle biogenesis |
| 02/09/2006 | WO2005093425A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 58 (gpr58) |
| 02/09/2006 | WO2005093423A3 Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara) |
| 02/09/2006 | WO2003040693A3 Peptides that home to tumor lymphatic vasculature and methods of using same |
| 02/09/2006 | WO2002088316A3 G-protein coupled receptors |
| 02/09/2006 | WO2001070095A3 Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| 02/09/2006 | US20060031956 Nucleotide sequences for gene regulation and methods of use thereof |
| 02/09/2006 | US20060030735 Adding a carbene-bearing or carbene equivalent-bearing compound across a double bond of an alkene compound to form a cyclopropyl ring, performing further chemical reactions on the additional functional groups incorporated |
| 02/09/2006 | US20060030720 Method for synthesizing macrosphelides |
| 02/09/2006 | US20060030713 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation |
| 02/09/2006 | US20060030598 Thiazolyl inhibitors of Tec family tyrosine kinases |
| 02/09/2006 | US20060030592 I-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels |
| 02/09/2006 | US20060030576 Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| 02/09/2006 | US20060030568 Crystal modificaion of a N-phenyl-2-pyrimidineamine derivative, processed for its manufacture and its use |
| 02/09/2006 | US20060030561 2-Benzyl-2-hydroxy-4-methyl-4-phenylpentanoic acid (1-oxo-1,3-dihydroisobenzofuran-5-yl)amide for example; treating type II diabetes, obesity, hypertension, arteriosclerosis, or glaucoma |
| 02/09/2006 | US20060030557 Substituted pyridines having antiangiogenic activity |
| 02/09/2006 | US20060030555 Imidazo(1,2-a)pyrazine compounds; cancers |
| 02/09/2006 | US20060030540 Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
| 02/09/2006 | US20060030045 Antisense modulation of c/ebp beta expression |
| 02/09/2006 | US20060030019 HDAC9 polypeptides and polynucleotides and uses thereof |
| 02/09/2006 | US20060030005 C3b/C4b complement receptor-like molecules and uses thereof |
| 02/09/2006 | US20060030001 Useful polypeptides |
| 02/09/2006 | US20060029687 comprises a carrier essentially formed of water, ethoxydiglycol and propylene glycol; anti-oxidant; high stirring speed provides for micronizaton of the components, which is responsible for the stability of the solutions |
| 02/09/2006 | US20060029681 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 02/09/2006 | US20060029606 Insulin-like growth factor (IGF); peptide of given sequence; administered with co-agent such as doxorubicin, paclitaxel, methotrexate, tamoxifen, cyclophosphamide, vincristine, etoposide, 5-fluorouracil; anticarcinogen |
| 02/09/2006 | US20060029596 Administering to the tumor an adenovirus vector, overexpresses an adenovirus death protein; promoting the death of neoplastic cells; telomerase resistance; anticancer biodrugs |
| 02/09/2006 | US20060029586 Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| 02/09/2006 | US20060029581 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 02/09/2006 | US20060029580 Method for treating a condition with neural progenitor cells derived from whole bone marrow |
| 02/09/2006 | DE69717294C5 Chinazolin derivate und diese enthaltende pharmazeutische zusammenstellungen Quinazoline derivatives and those containing pharmaceutical assortments |
| 02/09/2006 | DE102004043463A1 Differentiation of proteins, for use in diagnosis of cancer, comprises separating antigens from specimen electrophoretically and reacting with antibody composition |
| 02/09/2006 | DE102004036913A1 Verwendung von Pentameren zur Herstellung eines Medikaments Use of pentamers for the preparation of a medicament |
| 02/09/2006 | DE102004031538A1 Presentation form (obtainable by dissolving indibulin in or with a highly concentrated organic acid), useful to orally administer poorly soluble active compound indibulin, comprises a poorly soluble active compound indibulin |
| 02/09/2006 | CA2855056A1 A method of treating cancer comprising a vegf-b antagonist |
| 02/09/2006 | CA2612149A1 Mixture of catechins or rather polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy(bph) |
| 02/09/2006 | CA2592044A1 Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use |
| 02/09/2006 | CA2575986A1 Method of assuming drug sensitivity to cdk4 inhibitor |
| 02/09/2006 | CA2575901A1 A method of treating cancer comprising a vegf-b antagonist |
| 02/09/2006 | CA2575606A1 Hai-1 and hai-2 in cancer therapy |
| 02/09/2006 | CA2575552A1 Notch mutations leading to increased receptor signaling |
| 02/09/2006 | CA2575520A1 Prodrugs activated by rna-dependent dna-polymerases |
| 02/09/2006 | CA2575402A1 Humanized anti-cmet antagonists |
| 02/09/2006 | CA2575348A1 Novel anti-igf-ir antibodies and uses thereof |
| 02/09/2006 | CA2574966A1 Isoindoline compounds and methods of their use |
| 02/09/2006 | CA2574176A1 Induction of apoptosis in toll-like receptor expressing tumor cells |
| 02/09/2006 | CA2573573A1 Fused ring heterocycle kinase modulators |
| 02/09/2006 | CA2573362A1 Pyrrolo-pyridine kinase modulators |
| 02/09/2006 | CA2573103A1 Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
| 02/09/2006 | CA2571726A1 Prodrugs of hiv protease inhibitors |
| 02/09/2006 | CA2570321A1 Inhibitors of iap |
| 02/09/2006 | CA2568886A1 Compositions and methods for treatment of non-hodgkin's lymphoma |
| 02/08/2006 | EP1624057A2 Process for the obtention of a composition containing hyaluronidase |
| 02/08/2006 | EP1624055A1 Spheroid preparation |
| 02/08/2006 | EP1623990A2 Compositions and methods for the treatment of tumours |
| 02/08/2006 | EP1623989A1 Compositions and methods for the diagnosis of tumours |
| 02/08/2006 | EP1623985A2 Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventative agents |
| 02/08/2006 | EP1623721A1 Effector cell function inhibitor |
| 02/08/2006 | EP1623715A1 A composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin |
| 02/08/2006 | EP1623712A2 Selective estrogen receptor modulator in combination with dehydroepiandrosterone (DHEA) or analogues |
| 02/08/2006 | EP1623710A1 Receptor antagonist |
| 02/08/2006 | EP1623706A2 Metronomic dosing of taxanes for inhibiting tumor growth |
| 02/08/2006 | EP1623230A2 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39) |
| 02/08/2006 | EP1622942A2 Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| 02/08/2006 | EP1622937A2 Synthetic gene encoding human carcinoembryonic antigen and uses thereof |
| 02/08/2006 | EP1622924A2 8$g(b)-vinyl-11$g(b)-( g(v)-substituted)alkyl-estra-1,3,5(10)-trienes |
| 02/08/2006 | EP1622896A1 Novel aniline derivatives, their manufacture and use as pharmaceutical agents |
| 02/08/2006 | EP1622895A2 1-aryl-3-(indol-5-yl)-prop-2-en-1-ones, compositions comprising the same and use thereof |
| 02/08/2006 | EP1622894A1 Antitumoral antiadrogenic pyrrolidines |
| 02/08/2006 | EP1622883A2 Compounds, compositions, and methods |
| 02/08/2006 | EP1622878A2 Compounds, compositions and methods |
| 02/08/2006 | EP1622869A1 Glyoxalase inhibitors |
| 02/08/2006 | EP1622684A2 Compositions and methods relating to novel compounds and targets thereof |
| 02/08/2006 | EP1622650A2 Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy |
| 02/08/2006 | EP1622628A2 Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
| 02/08/2006 | EP1622624A1 Medicinal compositions comprising n-(3-chloro-1h-indol-7-yl)-4-sulfamoylbenzenesulfonamide and further cytostatics |
| 02/08/2006 | EP1622620A1 Quinazoline derivatives and their use in the treatment of cancer |
| 02/08/2006 | EP1622619A2 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 02/08/2006 | EP1622616A2 Inhibitors of akt activity |
| 02/08/2006 | EP1622608A2 Compositions and methods for treating cancer |
| 02/08/2006 | EP1622599A2 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |